CD274 and neoplasm: In line with these data, we demonstrate that dual treatment with anti-TIGIT Tiragolumab and anti-PD-L1 Durvalumab potentiates primary NK cell activity and anti-tumor cytotoxicity towards MB cell lines and PDX MB organoids (Figure 4).